The Role Of The Complement System In Rheumatic Diseases

Системата на комплемента играе ключова роля в имунитета на организма - от една страна пряко предпазва от патогени, подпомага хуморалния имунен отговор, очиства натрупаните имунни комплекси, апоптотични клетки и др. От друга страна дисрегулацията и свръхактивирането на комплемента, особено насочено срещу собствени структури има важни патогенетични последици при редица автоимунни заболявания. Участието на системата на комплемента в патогенезата на ревматологични заболявания е доказано, но изясняването на интимните механизми, които я свързват с намесените много други инфламаторни пътища, все още е предизвикателство. Целта на настоящия обзор е обобщение на последните научни данни за комплексното значение на системата на комплемента за развитието и прогресията на някои ревматологични заболявания, утвърдените до момента терапевтични стратегии, включващи инхибиране на комплементни компоненти и евентуалните бъдещи насоки за развитие на този интересен изследователски проблем.The complement system is a key player in immunity - on one hand it defends the organisms from pathogenes, helps the humoral response, clears the immune complexes, apoptotic cells, etc. On the other hand, dysregulation and overactivation of the complement, mostly targeted against own structures has important pathogenetic role in a number of autoimmune diseases. There is a growing body of evidence for the participation of the complement system in the pathogenesis of some rheumatic diseases, but unraveling the intimate mechanisms connecting it with the other numerous inflammatory pathways, is still a major challenge. In this review we try to summarize the scientific data for the complex role of the complement system in the development and progression of some rheumatic diseases; the established therapeutic strategies targeting complement components and the future perspectives for this field of research

Music reviews as part of mass culture

The status of contemporary Czech music reviews (also the Czech cultural criticism) ties in with mass culture and trends of postmodern thinking supports. Subjective journalist genres type reviews and critics look like the relevant expert testing about artistic performance, their real aim is economic profitability and fixing a position in their discourse domain. Mass culture can not offer an alternative to itselfa nd that's the reason, why central dichotomy variation - scheme is applicable not only to its products (music CDs, theatrical performances, a new book at he art), but also on the way, which is about these products further talks . Subjective meta - review has a the specific positron in the mass media

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

Objectives To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS). Methods This open-label extension study recruited patients with AS who completed a 54-week, randomised controlled study comparing CT-P13 with RP (PLANETAS). CT-P13 (5 mg/kg) was administered intravenously every 8 weeks from week 62 to week 102. Efficacy end points included the proportion of patients achieving Assessment of SpondyloArthritis international Society (ASAS)20. Antidrug antibodies (ADAs) were measured using an electrochemiluminescent method. Data were analysed for patients treated with CT-P13 in the main PLANETAS study and the extension (maintenance group) and those who were switched to CT-P13 during the extension study (switch group). Results Overall, 174 (82.9%) of 210 patients who completed the first 54 weeks of PLANETAS and agreed to participate in the extension were enro

Additional file 1: of Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

Overview of treatment-related SAEs occurring by severity, n (%). (DOC 31 kb

Additional file 1: of Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

Overview of treatment-related SAEs occurring by severity, n (%). (DOC 31 kb